NeuroPace (NASDAQ:NPCE) Stock Gets Downgrade from Leerink Partners

NeuroPace (NASDAQ:NPCE) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report issued on Friday, Marketbeat Ratings reports. They presently have a $7.00 target price on the stock. Leerink Partners‘s price target would suggest a potential downside of 41.76% from the stock’s current price.

A number of other equities research analysts have also weighed in on the company. Guggenheim restated a “neutral” rating on shares of NeuroPace in a research note on Wednesday, July 29th. KeyCorp started coverage on NeuroPace in a report on Thursday, September 17th. They set an “overweight” rating and a $18.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NeuroPace in a research report on Tuesday, September 15th. Raymond James Financial set a $21.00 target price on NeuroPace in a research report on Tuesday, September 15th. Finally, Weiss Ratings cut NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.00.

NeuroPace Stock Down 4.0%

Shares of NeuroPace stock opened at $12.02 on Friday. NeuroPace has a 1-year low of $11.90 and a 1-year high of $19.60. The company has a market capitalization of $412.53 million, a PE ratio of -21.09 and a beta of 1.98. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91. The business has a 50-day moving average of $13.35 and a 200-day moving average of $14.79.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. The business had revenue of $22.83 million for the quarter, compared to analysts’ expectations of $22.61 million. As a group, equities analysts forecast that NeuroPace will post -0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

Several hedge funds and other institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC raised its stake in shares of NeuroPace by 16.3% in the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock valued at $45,464,000 after purchasing an additional 401,201 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of NeuroPace in the 2nd quarter valued at about $39,369,000. Deutsche Bank AG bought a new position in shares of NeuroPace during the second quarter worth about $14,919,000. Algert Global LLC lifted its position in shares of NeuroPace by 2.9% during the second quarter. Algert Global LLC now owns 184,774 shares of the company’s stock worth $2,936,000 after purchasing an additional 5,218 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its position in shares of NeuroPace by 9.8% during the first quarter. Lazard Asset Management LLC now owns 124,305 shares of the company’s stock worth $1,635,000 after purchasing an additional 11,078 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

Recent NeuroPace Headlines

Here are a few of the latest headlines about NPCE:

• Positive Sentiment: NeuroPace reported a quarterly loss of $0.03 per share, narrower than the $0.11 loss analysts expected and the $0.11 loss a year earlier. Zacks article
• Negative Sentiment: Revenue was $23.1 million, below analysts’ $27.12 million expectation. RNS System revenue was $22.9 million, up just 1.4% year over year, pointing to limited growth. NeuroPace earnings release
• Negative Sentiment: The company lowered its 2026 revenue outlook to $91 million–$92 million, well below the roughly $100.4 million analyst consensus. The guidance reduction, alongside the quarterly revenue miss, is the clearest near-term negative catalyst for NPCE shares. Coverage of NeuroPace’s reduced guidance

NeuroPace Company Profile

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.